Royalty Pharma (NASDAQ:RPRX) Posts Earnings Results, Beats Expectations By $0.08 EPS
by Renee Jackson · The Cerbat GemRoyalty Pharma (NASDAQ:RPRX – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08, Zacks reports. The business had revenue of $631.00 million for the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.49%.
Here are the key takeaways from Royalty Pharma’s conference call:
- Royalty Pharma reported a strong Q1 with portfolio receipts up 10% and royalty receipts up 13%, delivered ~14% ROIC and ~20% ROIE, repurchased 1M shares for $50M, raised the 2026 guidance, and increased the dividend by 7%.
- The company is aggressively scaling R&D co-funding with Global Biopharma — announcing J&J and Teva deals totaling ~$1B this quarter — positioning to capture demand from an industry with >$1T projected R&D spend over five years.
- Material portfolio catalysts include Revolution Medicines’ daraxonrasib Phase III that nearly doubled overall survival in 2L pancreatic cancer, FDA approval of Denali’s Avlayah, and acquisition of a royalty on Ziihera (management cites >$2B peak sales potential and low‑double digit unlevered IRR).
- Financial flexibility remains strong with $586M cash, ~$722M portfolio cash flow in Q1, $9.2B of long‑dated investment‑grade debt (12‑yr avg duration), an undrawn $1.8B revolver and a recent Fitch upgrade to BBB, giving ~ $4B+ access to capital.
- Near‑term risks include lower expected milestones (from $128M in 2025 to ~$60M in 2026), headwinds from Promacta LOE, potential US biosimilar TYSABRI and IRA impacts, and an arbitration with Vertex now expected to resolve around mid‑2027.
Royalty Pharma Stock Performance
RPRX traded up $0.59 during trading on Friday, hitting $50.79. 3,764,589 shares of the company traded hands, compared to its average volume of 3,543,437. Royalty Pharma has a one year low of $32.15 and a one year high of $51.65. The stock’s fifty day moving average is $47.62 and its 200 day moving average is $42.75. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The firm has a market cap of $29.30 billion, a P/E ratio of 34.55, a price-to-earnings-growth ratio of 3.24 and a beta of 0.40.
Royalty Pharma Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.9%. Royalty Pharma’s dividend payout ratio is presently 63.95%.
Wall Street Analyst Weigh In
RPRX has been the subject of several analyst reports. Morgan Stanley increased their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. JPMorgan Chase & Co. raised their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Citigroup boosted their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $53.71.
Get Our Latest Stock Report on Royalty Pharma
Insiders Place Their Bets
In other news, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 139,164 shares of company stock valued at $6,624,902 in the last 90 days. 18.84% of the stock is owned by insiders.
Institutional Investors Weigh In On Royalty Pharma
A number of hedge funds have recently modified their holdings of the stock. Vident Advisory LLC purchased a new stake in Royalty Pharma in the second quarter worth $261,000. Quantitative Investment Management LLC bought a new stake in shares of Royalty Pharma in the third quarter valued at $259,000. Blair William & Co. IL lifted its position in shares of Royalty Pharma by 6.8% during the 3rd quarter. Blair William & Co. IL now owns 7,263 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 462 shares during the last quarter. Brooklyn Investment Group purchased a new position in shares of Royalty Pharma during the 4th quarter valued at $222,000. Finally, Atlas Capital Advisors Inc. bought a new position in shares of Royalty Pharma during the 4th quarter worth $221,000. Institutional investors own 54.35% of the company’s stock.
Royalty Pharma Company Profile
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.